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Abstract. Raf-1 kinase inhibitory protein (RKIP), an endog-
enous inhibitor of the extracellular signal-regulated kinase 
(ERK) pathway, suppresses metastasis in a number of cancer 
types, including colorectal carcinoma (CRC); thus, RKIP 
downregulation significantly contributes to CRC invasive-
ness and metastatic potential. However, our previous study 
demonstrated that RKIP‑positive tumors in CRC patients 
are predictive of hepatic colorectal metastases (HCMs). 
Based on the previous finding that the ERK pathway can 
be activated independently of RKIP, we hypothesized that 
RKIP‑expressing HCMs may express significant levels of 
phosphorylated ERK (pERK). Thus, the present study evalu-
ated the expression of RKIP and pERK in 68 HCM tissue 
samples using immunohistochemistry. RKIP expression was 
positive in 22 (32.4%) of the 68 samples, seven (31.8%) of 
which exhibited nuclear pERK immunoreactivity exclusively 
at the invasive tumor front. Furthermore, pERK expression 
at the invasive front was significantly associated with recur-
rent HCM following hepatic resection, and pERK expression 
observed at the invasive front of RKIP‑expressing HCMs 
indicated that the activation of the ERK pathway may also 
be involved in the invasive process of these tumors, despite 
the presence of RKIP. A strong association between pERK 
expression and the presence of recurrent HCM may indicate 
that the ERK pathway is important in the metastatic recur-
rence of RKIP‑positive HCM.
Introduction
Colorectal carcinoma (CRC) is one of the most common 
types of solid malignancy and a main cause of cancer-related 
mortality globally. Colorectal carcinogenesis is a complex 
multistep process that involves progressively disrupting intes-
tinal epithelial cell proliferation, differentiation, apoptosis and 
survival mechanisms (1,2). Mitogen‑activated protein kinases 
(MAPKs), members of a large family of serine‑threonine 
kinases, form major cell proliferation signaling pathways 
from the cell surface to the nucleus (3), and can be activated 
in response to a wide range of extracellular stimuli (4). The 
first member of this family to be characterized was extracel-
lular signal-regulated kinase (ERK). The ERK pathway is 
important for cell survival and proliferation, and a number of 
key growth factors and proto‑oncogenes act via this cascade, 
transducing the signals to promote cell growth and differen-
tiation (5). For example, activated Ras activates Raf‑1, which 
in turn phosphorylates and activates MAPK/ERK kinase 
(MEK), resulting in activation of ERK, the only known 
substrate of MEK. Analysis of established cell lines indicates 
that constitutive activation of MAPK is induced in tumors in a 
tissue‑specific manner; for example, tumor cells derived from 
CRC tissues exhibit a particularly high frequency of ERK acti-
vation (6). Furthermore, increasing evidence indicates that the 
ERK pathway is important for regulating apoptosis and cell 
proliferation, and that its activation is involved in the tumori-
genesis, progression and oncogenic behavior of CRC (7‑12).
Raf-1 kinase inhibitory protein (RKIP), a member of 
the phosphatidylethanolamine binding protein family, was 
initially identified as an endogenous inhibitor of the ERK 
pathway. By binding to Raf‑1 or MEK, RKIP interferes with 
MEK activation by Raf‑1, thus inhibiting ERK activation (13). 
Our previous studies demonstrated that RKIP downregulation 
significantly contributes to the invasiveness and metastatic 
potential of a number of different types of human carcinoma, 
including CRC (14‑19); for example, it was identified that 
RKIP expression was significantly reduced in metastatic tumor 
tissues compared with corresponding primary tumor and 
non‑neoplastic tissues (15,17,18,20). In addition, a reduction in 
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RKIP expression levels was associated with lymphovascular 
invasion, as well as nodal and distant metastases, increased 
local recurrence, advanced tumor stage and decreased survival 
rate (14‑16,18). Furthermore, RKIP downregulation appeared 
to correlate with aggressive oncogenic behavior. Thus, the data 
indicated that RKIP may act as a suppressor of metastasis in 
CRC.
However, our previous studies determined conflicting 
results regarding the association between RKIP expres-
sion and metastasis in specific CRC patients, for example, 
hepatic colorectal metastasis (HCM) was histopathologically 
diagnosed in CRC patients whose tumors exhibited positive 
RKIP immunoreactivity (19). This finding indicated that 
metastatic properties are preserved in a certain group of tumor 
cells despite the presence of the metastatic suppressor RKIP. 
Furthermore, previous studies demonstrated that ERK can 
be phosphorylated regardless of RKIP status (21,22). Based 
on these data, we hypothesized that the ERK pathway may 
be activated in RKIP‑expressing HCM tissues, and that the 
activation of this pathway may be involved in the invasive 
process of HCM cells.
Therefore, the present study investigated whether phos-
phorylated ERK (pERK) is detectable in RKIP-expressing 
HCM tissues. In addition, the association between pERK 
expression and various clinicopathological characteristics of 
HCM patients was evaluated to assess its clinical value.
Patients and methods
Patient and tissue specimens. Human HCM tissue samples 
were obtained from 68 consecutive patients (46 male and 
22 female; median age, 61 years; mean age, 60.1 years) who 
underwent surgery at the Kyung Hee University Hospital 
(Seoul, Korea) between January 2005 and December 2012. 
All of the patients met the following criteria for hepatic resec-
tion with intent to cure: i) No signs of extrahepatic metastases 
in pre‑operative imaging, including chest X‑ray, abdominal 
ultrasonography and abdominopelvic computed tomography; 
ii) HCM that allowed adequately sized, well‑vascularized 
hepatic remnants to remain following hepatic resection; and 
iii) medical fitness for major hepatic resection. Only patients 
whose metastases were resectable on presentation were 
included in the present study. The resected lesions were stained 
with hematoxylin and eosin and reviewed by two independent 
pathologists, who selected the most representative slide from 
each case for subsequent immunohistochemical staining. The 
selected tissues were fixed in 10% neutral buffered formalin for 
24‑72 h at room temperature for paraffin embedding prior to 
analysis. Furthermore, the following clinicopathological data 
was assessed in each case: Patient age and gender, size, number 
and distribution of HCMs, HCM recurrence and survival data 
obtained from follow-up after hepatic resection. Informed 
consent was obtained from all participants. The study was 
approved by the institutional review board of the Republic of 
Korea Air Force Aerospace Medical Center (Cheongju, Korea).
Immunohistochemistry. RKIP and pERK protein expres-
sion was assessed by immunohistochemistry using the Bond 
Polymer Intense Detection System (Leica Biosystems, Seoul, 
Korea), according to the manufacturer's instructions. Briefly, 
4‑µm sections of formalin‑fixed, paraffin‑embedded tissue 
were deparaffinized with Bond Dewax solution (Leica Biosys-
tems) and an antigen retrieval procedure was performed using 
Bond Epitope Retrieval solution 1 (cat. no. AR9961; Leica 
Biosystems) for 30 min at 100˚C. Endogenous peroxidases 
were blocked by incubation with hydrogen peroxide for 5 min 
and the sections were incubated for 15 min at ambient temper-
ature with a 1:200 dilution of rabbit polyclonal anti-RKIP 
(cat. no. sc‑32623; Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) or rabbit monoclonal anti‑pERK (phospho‑p44/42 
MAPK [Thr202/Tyr204; clone, 20G11]; cat. no. 4376S; Cell 
Signaling Technology, Inc., Beverly, MA, USA). Staining was 
performed using a biotin-free polymeric horseradish perox-
idase‑linker antibody conjugate system with the Bond Max 
automatic slide stainer (Leica Biosystems), and the slides were 
visualized with 3,3'‑diaminobenzidine (DAB) solution [1 mm 
DAB, 50 mm Tris‑HCl buffer (pH 7.6) and 0.006% H2O2]. In 
addition, the nuclei were counterstained with hematoxylin and 
the slides were dehydrated through a series of graded alcohols 
(70, 90 and 100%), cleared in xylene (Sigma Aldrich, St. Louis, 
MO, USA) and sealed with coverslips. Positive control samples 
consisted of healthy colonic mucosa for RKIP, and prostate 
carcinoma and malignant melanoma for pERK (23,24). The 
negative control was prepared by substituting non‑immune 
serum for primary antibody and resulted in no detectable 
staining.
Evaluation of immunohistochemical staining. Two expe-
rienced independent pathologists, who were blinded to the 
clinicopathological data and outcomes of the patients, exam-
ined the immunohistochemical expression of RKIP and pERK 
in the stained sections. Immunoreactivity for RKIP and pERK 
was analyzed using previously described semi‑quantitative 
scoring methods (14‑20), and the scores of the two pathologists 
were compared, with discrepancies resolved by re‑examination 
by the two pathologists to achieve a consensus score. The final 
score was the sum of the scores for the percentage of positive 
tumor cells (0, 0%; 1, ≤25%; 2, 25‑50%; and 3, >50%) and the 
staining intensity (0, absent; 1, faint; 2, moderate; 3, strong). 
Additionally, expression scoring was follows: 0‑2, negative 
expression; 3‑4, weak expression; and 5‑6, positive expression. 
All the immunostaining scores were determined at the center, 
intermediate zone and invasive front of the tumor, as well as at 
subcellular locations.
Statistical analysis. Fisher's exact test was performed to 
determine whether pERK expression was associated with each 
HCM clinicopathological characteristic, and a survival anal-
ysis was used to examine the prognostic significance of pERK 
expression in the HCM patients by producing survival curves 
using the Kaplan‑Meier method and applying a log‑rank test 
to analyze any statistical differences. All statistical analyses 
were performed using SPSS software (version 15.0; SPSS Inc., 
Chicago, IL, USA) and P<0.05 was used to indicate a statisti-
cally significant difference.
Results
Overall, RKIP immunoreactivity appeared to be predomi-
nantly cytoplasmic and homogeneous throughout the tumor, 
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with protein expression levels determined to be negative in 
36.8% (25/68; Fig. 1A), weak in 30.8% (21/68) and positive in 
32.4% (22/68; Fig. 1B) of samples. Of the 22 RKIP‑expressing 
cases, seven (31.8%) exhibited intense nuclear and moderate 
cytoplasmic pERK immunoreactivity (Fig. 1C), while the 
remaining 15 cases (68.2%) exhibited no pERK immuno-
reactivity (Fig. 1D). In contrast to RKIP expression, pERK 
immunoreactivity was heterogeneous and strongly positive 
pERK protein expression was exclusively detected at the 
invasive tumor front, whereas the tumor center and inter-
mediate zones did not display pERK immunoreactivity. 
Furthermore, only cells that faced the hepatic parenchyma 
expressed pERK, forming a band‑like pattern (Fig. 1C). This 
unique localization of pERK was accompanied by loss of the 
epithelial phenotype, and characterized by the detachment 
of small isolated clusters of tumor cells and a dedifferenti-
ated morphology at the invasive front. By contrast, cells in 
the center and intermediate zones of the tumor exhibited a 
typical epithelial growth pattern characterized by adherent 
polarized cells forming clear trabecular or tubular structures. 
In addition, pERK staining exhibited strong staining intensity 
in the nucleus, consistent with ERK activity being highest in 
this subcellular location.
The association between pERK expression at the invasive 
front and the clinicopathological characteristics of HCM is 
Table I. Association between pERK expression at the invasive 




Characteristic (n=7) (n=15) P‑value
Age, n (%)
  ≥61 years 4 (57.1) 6 (40.0) 0.652
  <61 years 3 (42.9) 9 (60.0)
Gender, n (%)
  Male 5 (71.4) 10 (66.7) 1.000
  Female 2 (28.6) 5 (33.3)
HCM, n (%)
  Single 4 (57.1) 11 (73.3) 0.630
  Multiple 3 (42.9) 4 (26.7)
HCM size, n (%)
  ≥2.5 cm 3 (42.9) 8 (53.3) 1.000
  <2.5 cm 4 (57.1) 7 (46.7)
HCM distribution, n (%)
  Unilobar 6 (85.7) 12 (80.0) 1.000
  Bilobar 1 (14.3) 3 (20.0)
HCM recurrence, n (%)
  Present 7 (100.0) 1 (6.7) <0.001a
  Absent 0 (0.0) 14 (93.3)
Median survival (range), 26 (1‑62) 28 (6‑85) 0.853
monthsb
aStatistically significant. pERK, phosphorylated extracellular 
signal‑regulated kinase; HCM, hepatic colorectal metastasis. 
Figure 1. Immunoreactivity for Raf‑1 kinase inhibitory protein (RKIP) and 
phosphorylated extracellular signal-regulated kinase (pERK) in hepatic 
colorectal metastasis (HCM) samples. (A) Negative RKIP expression in 
tumor cells; and (B) positive RKIP expression in the cytoplasm of tumor 
cells, with adjacent hepatocytes (right lower corner) used as the internal 
positive controls. (C) Positive pERK expression in tumor cells demonstrating 
selective expression of pERK at the invasive front of HCM, but not the inner 
areas. pERK expression formed a band‑like pattern (inset) and localization of 
pERK was accompanied with loss of the epithelial phenotype, characterized 
by the detachment of small isolated clusters of tumor cells and dedifferen-
tiation. Tumor cells invading the hepatic parenchyma exclusively expressed 
pERK in the nucleus and cytoplasm. (D) Negative pERK expression in tumor 
cells. (stain, polymer method; A‑D, magnification, x200).
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indicated in Table I. It was observed that pERK expression at 
the invasive front was significantly associated with recurrent 
HCM (P<0.001); all patients with pERK‑positive tumors devel-
oped recurrent HCM, while in patients who did not develop 
recurrent HCM, pERK expression was absent. The prediction 
of recurrent HCM was associated with pERK expression at the 
invasive front, with 87.5% sensitivity, 100% specificity, a 100% 
positive predictive value and a 93.3% negative predictive value.
Discussion
Histopathological studies have demonstrated that invasiveness, 
characterized by the loss of epithelial differentiation and the 
acquisition of a mesenchymal phenotype, is predominantly 
observed at the periphery of CRC tumors (25‑27), with cells 
at the invasive front considered to exhibit a higher malignant 
potential than the inner areas of the same tumor. Previous 
studies utilized CRC cell lines and surgical specimens to 
demonstrate that the ERK pathway is critical for the invasive and 
proliferative properties of these tumors (6,25,28,29). Further-
more, pERK was expressed at higher levels in more advanced 
stages of CRC, demonstrating the importance of this molecule 
in CRC progression, invasion and metastasis (2). In the present 
study, the selective localization of pERK was identified at the 
invasive front of a subpopulation of metastasized CRC cells, 
but not in the inner, more differentiated areas of the tumor, and 
pERK expression was accompanied by the loss of the epithelial 
phenotype. This pERK expression pattern is consistent with 
the results of the aforementioned studies and possibly reflects 
the high biological aggressiveness of tumor cells at the invasive 
edge. Activation of the ERK pathway initiates transcription, 
which leads to the expression of matrix metalloproteinase and 
myosin light-chain kinase, inducing degradation of the basement 
membrane and promoting cell migration and invasion (30‑32). 
Additionally, recent studies into the functional role of pERK in 
carcinomas revealed that pERK upregulation augmented cell 
motility on extracellular matrix components, increased Matrigel 
invasion and promoted the growth of the tumor (33‑35). To the 
best of our knowledge, the distinct distribution of pERK at the 
invasive front of HCM has yet to be reported, and the findings of 
the present study indicate that pERK is significant in the HCM 
invasive process in vivo, which supports the previous finding 
that activation of the ERK pathway is necessary for the induc-
tion of epithelial cell dedifferentiation (36).
Furthermore, the current study detected intense pERK 
immunoreactivity in RKIP‑expressing metastatic tumors. 
Although oncogenic pathways other than the ERK cascade 
may contribute to CRC cell dissemination in RKIP-expressing 
tumors, the possibility that the ERK pathway may be involved 
in the metastatic process regardless of RKIP status must be 
considered, thus, the present study proposes a number of 
possible explanations for this result. Firstly, the ERK cascade 
is not a simple linear pathway, but has numerous positive and 
negative regulatory components, which function at all levels 
of the cascade (37). For example, a previous study demon-
strated that RKIP regulates Raf-1, but not B-Raf, indicating 
that B‑Raf is able to phosphorylate and activate MEK and 
ERK independent of RKIP (22). Papin et al (21) reported 
that B‑Raf displayed higher MEK kinase activity compared 
with Raf-1. Based on these data, the present study proposes 
that BRAF mutations may be involved in ERK activation 
in RKIP-expressing tumors. Secondly, in addition to the 
predominant MEK activators Raf‑1 and B‑Raf, MEK kinase‑1 
and A‑Raf are able to phosphorylate MEK and thus activate 
the ERK pathway, although the biochemical potency of A-Raf 
is much weaker than that of Raf‑1 or B‑Raf (38). Finally, MEK 
is capable of autophosphorylation, resulting in an increase in 
MEK kinase activity (39). Thus, although the observation of 
pERK expression at the invasive front of RKIP‑expressing 
HCMs indicates that the activation of the ERK pathway 
contributes to the invasive process in RKIP‑expressing meta-
static tumor cells, additional studies are required to clarify or 
disprove the findings of the present study.
The treatment of primary CRC with surgical resection, 
combined with chemotherapy or radiation therapy in certain 
cases, is curative in a number of patients, however, almost half 
will develop HCM during the disease course (40). Further-
more, even when hepatic resection is performed with curative 
intent, the majority of patients experience tumor recur-
rence (41); one‑third of which develop recurrent metastases 
isolated to the liver. Repeat hepatic resection for recurrent 
HCM appears to be warranted in carefully selected patients 
due to the reasonable survival expectations, similar to those 
of patients undergoing single hepatic resection (42). In this 
regard, identifying markers based on biological determinants 
may facilitate the improvement and earlier stratification of 
patients according to recurrence risk, and aid in selecting 
patients who may benefit from repeated hepatic resection. 
The present study demonstrated that pERK expression was 
significantly associated with recurrent HCM, and high sensi-
tivity, specificity and predictive values indicated that pERK 
expression at the invasive front of HCM may be used as a 
novel biomarker for the prediction of recurrent HCM.
In conclusion, the present study identified the unique, 
heterogeneous expression of pERK in HCM and its associa-
tion with metastatic recurrence. The selective upregulation of 
pERK at the invasive tumor front indicates that activation of 
the ERK pathway is involved in the invasive process of HCM 
cells. In addition, pERK expression at the invasive front of 
HCM was strongly associated with HCM recurrence, with 
high sensitivity, specificity and predictive values. These find-
ings indicate that pERK expression may be used as a novel 
predictive biomarker of metastatic recurrence and an effec-
tive target for therapeutic strategies against RKIP‑expressing 
HCM.
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